On this page, you will find different kinds of study results:
• A Lay summary which is a summary of clinical trial results written in an easy-to-understand way.
• A summary of results called synopsis which is written in scientific language. It is prepared for Medicines Agencies and Ethics Committees,
• A scientific publication which presents results for scientists and medical doctors.
226 Results
| Protocol Code |
Study Title |
Active substance/Medical device |
Study Phase |
Therapeutic Area |
| CL3-20098-041 |
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg)…
|
AGOMELATINE,
S020098
|
Phase 3
|
Neuropsychiatric Diseases
|
|
| CL3-18886-012 |
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a…
|
TERUTROBAN,
S018886
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-102 |
Effects of ivabradine on plaque burden, morphology and composition in patients with clinically indicated coronary…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-098 |
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-097 |
Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-083 |
Effects of ivabradine in patients with stable coronary artery disease without clinical heart failure. A…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-078 |
Effects of a 10 or 15 mg single intravenous bolus of ivabradine versus placebo on…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-068 |
Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-067 |
Long-term (3 years) ophthalmic safety and cardiac efficacy and safety of ivabradine administered orally at…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-064 |
Evaluation of the anti-anginal efficacy and safety of ivabradine used in combination with an anti-anginal…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-063 |
Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-057 |
Evaluation of the anti-anginal efficacy and safety of oral administration of ivabradine compared to placebo…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-16257-056 |
Effects of ivabradine on cardiovascular events in patients with stable coronary artery disease and left…
|
IVABRADINE,
S016257
|
Phase 3
|
Cardiovascular Diseases
|
|
| CL3-12911-040 |
Knee joint replacement over 5 years in patients with knee osteoarthritis. A long term follow…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-038 |
A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-037 |
A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs.…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-036 |
Effect of strontium ranelate (2g per day) in the management of long bone fractures with…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-035 |
A multicenter, prospective, randomized, double-blind, placebo-controlled, international study to assess the effects of 2g per…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-032 |
The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis. A…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-030 |
A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-028 |
Long-term effects of strontium ranelate on knee osteoarthritis symptoms. A 2-year prospective, randomised, placebo-controlled study.
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-025 |
A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-022 |
The efficacy and safety of two doses of strontium ranelate versus placebo administered orally for…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-019 |
A double-blind, multicentric, multinational randomised study to assess the effects of one year administration of…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
| CL3-12911-018 |
The efficacy and safety of two doses of strontium ranelate (1g and 2g per day)…
|
STRONTIUM RANELATE,
S012911
|
Phase 3
|
Rheumatology
|
|
Servier clinical trials are mainly registered on
EU Clinical Trials Register
The EU Clinical Trials Register contains information on interventional clinical trials on medicines carried out in Europe, which started after 1 May 2004.
SEE MORE
ClinicalTrials.gov
Clinicaltrials.gov is a registry that contains information on clinical studies of human participants carried out around the world.
SEE MORE
ISRCTN registry
The International Standard Randomized Controlled Trial Number (ISRCTN) registry is a primary clinical trial registry recognised by World Health Organization (WHO) and International Committee of Medical Journal Editor (ICMJE) that accepts all clinical research studies.
SEE MORE
